Piramal Pharma to Announce Q1FY26 Results on July 28
By Shishta Dutta | Updated at: Jan 9, 2026 01:55 PM IST
Mumbai, July 18 – Piramal Pharma Limited (NSE: PPLPHARMA) has notified that its Board of Directors will meet on July 28, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1FY26). The investors would look forward to higher growth compared to Q4 FY25. The last quarter saw modest revenue growth (~8%) and strong cash-flow metrics, amid ongoing capacity expansions in Lexington, Turbhe, and Pithampur.
This marks the company’s first financial disclosure for FY26, following a year of consistent sequential growth and improved profitability.
Piramal Pharma Stock Performance
The share closed at ₹211.18 (down by 2.63% from the previous day’s close). The high and low ranges remained between ₹209.50 and ₹217.60. The traded volume was also on the higher side (42,63,864 shares).
Recent Quarterly Performance (Standalone)
| Quarter Ended | Total Income (₹ lakh) | Profit Before Tax (₹ lakh) | Net Profit (₹ lakh) | EPS (₹) | Announcement Date |
|---|---|---|---|---|---|
| 31 Mar 2025 | 1,72,931.00 | 36,436.00 | 27,727.00 | 2.09 | 14-May-2025 |
| 31 Dec 2024 | 1,27,302.00 | 15,941.00 | 11,880.00 | 0.90 | 28-Jan-2025 |
| 30 Sep 2024 | 1,39,077.00 | 27,571.00 | 21,006.00 | 1.59 | 23-Oct-2024 |
| 30 Jun 2024 | 1,09,996.00 | 11,166.00 | 8,527.00 | 0.64 | 26-Jul-2024 |
| 31 Mar 2024 | 1,57,849.00 | 36,267.00 | 27,308.00 | 2.06 | 10-May-2024 |
The company’s Q4FY25 standalone net profit rose to ₹27,727 lakh, marking a sequential increase of 133.3% from Q3FY25 and a YoY increase of 1.5% from Q4FY24. Total income also climbed to ₹1,72,931 lakh, up 57.2% QoQ.
Outlook Ahead of Q1FY26
With improving operating leverage and margin expansion in recent quarters, analysts will closely watch for early FY26 trends, particularly in international sales, cost efficiencies, and product mix evolution.
Company Overview
Piramal Pharma Limited is listed on the NSE and operates across contract development and manufacturing (CDMO), complex hospital generics, and Indian consumer healthcare. The company continues to strengthen its global presence, focusing on innovation-led growth.
REF: https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_60120_1486386_18072025024202_WEB.xml
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
